Toxicity spectrum of immunotherapy in advanced lung cancer: A safety analysis from clinical trials and a pharmacovigilance system

BACKGROUND: With the increased use of immune checkpoint inhibitors (ICIs) in advanced lung cancer, adverse events (AEs), particularly immune-related AEs (irAEs), have garnered considerable interest. We conducted a comprehensive assessment of the toxicity profile in advanced lung cancer using multi-s...

Descripción completa

Detalles Bibliográficos
Autores principales: Yan, Yi-Dan, Zhao, Ying, Zhang, Chi, Fu, Jie, Su, Ying-Jie, Cui, Xiang-Li, Ma, Er-Li, Liu, Bing-Long, Gu, Zhi-Chun, Lin, Hou-Wen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9256649/
https://www.ncbi.nlm.nih.gov/pubmed/35812997
http://dx.doi.org/10.1016/j.eclinm.2022.101535

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9256649/
https://www.ncbi.nlm.nih.gov/pubmed/35812997
http://dx.doi.org/10.1016/j.eclinm.2022.101535

Ejemplares similares